Efficacy and safety of colorectal endoscopic submucosal dissection in patients with sarcopenia

• Published in: Surgical endoscopy Vol. 35; no. 10; pp. 5489 - 5496
• Main Authors: Goto, Shungo, Arimoto, Jun, Higurashi, Takuma, Takahashi, Kota, Ohkubo, Naoki, Kawamura, Nobuyoshi, Tamura, Tetsuya, Tomonari, Hisakuni, Iwasaki, Akito, Taniguchi, Leo, Chiba, Hideyuki, Atsukawa, Kazuhiro, Saigusa, Yusuke, Nakajima, Atsushi
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2021; Springer Nature B.V
• Subjects: Abdominal Surgery; Colorectal cancer; Comorbidity; Dissection; Endoscopy; Ethics; Gastroenterology; Gynecology; Hepatology; Hospitals; Medical prognosis; Medicine; Medicine & Public Health; Musculoskeletal system; Patients; Proctology; Risk factors; Sarcopenia; Surgery; Tumors; Sarcopenia; Endoscopic submucosal dissection; Colorectal neoplasms
• ISSN: 0930-2794; 1432-2218
• DOI: 10.1007/s00464-020-08041-1

Background Endoscopic submucosal dissection (ESD) for early-stage colorectal cancer (CRC) has become a common and useful treatment. Although sarcopenia has been identified as an independent risk factor for complications after surgery for CRC, whether sarcopenia is also an independent risk factor for complications after colorectal ESD remains to be clarified. The aim of this study was to compare the outcomes of colorectal ESD in patients with and those without sarcopenia. Methods This is a retrospective cohort study. A total of 334 patients underwent colorectal ESD for 361 neoplasms at Hiratsuka City Hospital from March 2012 to October 2018. The neoplasms were divided into two groups depending on the presence or absence of sarcopenia in the patients. Results Overall, 334 patients underwent colorectal ESD for 361 neoplasms during the study period. We excluded 90 patients (90 neoplasms), and 244 patients (277 neoplasms) were included in the final analysis (134 from the sarcopenia group, 137 from the non-sarcopenia group). The en-bloc resection rate was high and was not significantly different between the sarcopenia group [126/134 (94.1%)] and the non-sarcopenia group [133/137 (97.1%)], P  = 0.1778). The rate of perforation and the rate of delayed bleeding were not significantly different between the sarcopenia group and the non-sarcopenia group [6/134 (4.5%) vs. 9/137 (6.6%), P  = 0.314, 4/134 (3%) vs. 6/137 (4.4%), P  = 0.3885, respectively]. Conclusions The presence of sarcopenia did not influence the rate of complications after ESD. Colorectal ESD is safe and effective even in patients with sarcopenia. Prospective multicenter studies are necessary to confirm our results.